P69. Ki-67 auto-antibodies in colorectal cancer patients  by Duchrow, M. et al.
52 E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 2 7 –5 3applied LOOCV, we were able to correctly predict the tumor
behavior (T-level down-sizing) in 83% of patients (p = 0.02). We
then observed that after a median follow-up of 34.5 months, all
five patients with metastatic disease belonged to the group of
non-responders. We again applied LOOCV and correctly predicted
all five patients with recurrence. Furthermore, all 11 patients who
were predicted to remain cancer free showed no evidence of
recurrence.
Conclusion: Our results suggest that pretherapeutical gene
expression profiling may assist in response prediction of rectal
adenocarcinomas to preoperative CT/RT and in prediction of dis-
ease free survival if validated in larger independent studies.
doi:10.1016/j.ejcsup.2006.04.127
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Background: Colorectal carcinomas develop through the
sequential stages of increasing morphological and molecular
alterations. While the correlation of tumor phenotype with asso-
ciated genomic alterations has been firmly established, the corre-
lation with global gene expression profiles is less.
Methods: We analyzed tissue samples from 36 patients to iden-
tify sequential alterations of the genome and transcriptome that
define the transformation of normal epithelium and the progres-
sion from adenomas to invasive disease.
Results: Comparative genomic hybridization (CGH) revealed pat-
terns of stage specific, recurrent genomic imbalances. Gene
expression analysis on 9K cDNA arrays identified 58 genes to be
differentially expressed between normal mucosa and adenoma,
116 genes between adenoma and carcinoma, and 158 genes
between primary carcinoma and liver metastasis (p < 0.001). Our
analysis revealed a direct correlation of chromosomal copy num-
ber changes with chromosome-specific average gene expression
levels.
Conclusion: Increasing genomic instability, a recurrent pattern
of chromosomal aberrations and a specific gene expression pat-
tern correlate with distinct stages of colorectal cancer progres-
sion. Chromosomal aneuploidies exert a direct effect on average
expression levels of the genes residing on the aneuploid chromo-
somes, thereby contributing to a massive deregulation of the cel-
lular transcriptome. The identification of novel genes and
proteins might deliver relevant molecular targets for diagnostic
and therapeutic interventions.
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Background: Antibodies against the human nuclear antigen pKi-
67 (Ki-67, MIB-1) are routinely used in oncology as immune-histo-
logical proliferation marker. PKi-67 is exclusively expressed in all
active phases of the cell cycle (G1,S, G2, Mitosis). The Ki-67 index
(relative number of positive stained nuclei) serves as an indepen-
dent prognostic marker for certain tumor entities. We investigated
whether colorectal cancer patients express auto-antibodies
against pKi-67 and whether this has a prognostic relevance.
Methods: Auto-antibodies were detected by Western blot stain-
ings from SW480 nuclear extracts with 36 pre- and 65 post-oper-
ative sera of colorectal cancer patients’ sera. Sera of 20 voluntary
healthy donors served as negative control. The same samples
were simultaneously tested for p53 auto-antibodies.
Results: Thirteen percent of the sera proved to be positive for
pKi-67 auto-antibodies while the control sera were completely
negative. p53 auto-antibodies could be found in 53% of the patient
sera. 75% anti-pKi-67 positive samples were also anti-p53 posi-
tive. For both antigens we found less positive antibodies in
post-operative sera (pKi-67: 9%; p53: 42%) than in pre-operative
sera (pKi-67: 19%, p53: 61%). There was, however, no significant
correlation between pKi-67 positive sera and tumor stage (I:
13%, II: 4%; III: 23%; IV: 13%), grading or patient’s prognosis.
Remarkably, there is a significant (p = 0,023) correlation of pKi-
67 positive sera of colon cancer patients (77%) in comparison to
rectal cancer patients (60%).
Conclusion: PKi-67 auto-antibodies could be diagnostically valu-
able in the early detection of neoplasia and could be used as
potential markers for recurrent or metastatic disease.
doi:10.1016/j.ejcsup.2006.04.129
P70. TRANSCRIPTIONAL AND MOLECULAR REGULATORS
OF THE UROKINASE-RECEPTOR-(u-PAR)-GENE: FIRST ANALYSIS
OF INDEPENDENT PROGNOSTIC RELEVANCE IN RESECTED
COLORECTAL CANCER
Gabriele D. Maurera, Joerg H. Leupolda, Denis M. Scheweb, Tobias
Billera, Ronald E. Katesd, Hans-Martin Hornungc, Ulla Lau-Wernerc,
Stefan Poste, Heike Allgayera. aDepartment of Experimental Surgery
and Molecular Oncology of Solid Tumors, Klinikum Mannheim,
University Heidelberg, and DKFZ Heidelberg, Germany; bDepartment
of Pediatrics, Dr. v. Haunersches Kinderspital, Ludwig-Maximilians-
University Munich, Germany; cKlinikum Grosshadern, Ludwig-
Maximilians-University Munich, Germany; dTechnical University
Munich, Germany; eDepartment of Surgery Mannheim, University
Heidelberg, Germany.
Purpose: Prognostic studies on transcription factors acting at
specific promoter elements have never been performed so far.
In previous studies we showed that the invasion-related gene u-
PAR is regulated especially via an AP-2/Sp1(-152/-135)-, and an
AP-1-promoter motif(-190/-171), mediating u-PAR-induction by
